drugset
drugset / Trial / NCT02903095

Single Ascending Dose Study of TD-1439 in Healthy Subjects

NCT02903095 ↗

Phase 1 Completed 66 enrolled Theravance Biopharma
RandomizedParallel-groupDouble-blindBasic science

Summary

Single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy subjects

Timeline

Start
2016-09
Primary completion
2016-12
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject TD-1439 Unknown — —

Indications

No indication recorded.